News vTv's azeliragon is latest Alzheimer's drug failure vTv to stop all studies after STEADFAST trial failure
News Biotech vTv believes small molecule GLP-1 pill can take on b... Pill could be effective in diabetes, with fewer GI effects.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
